Literature DB >> 19106733

Identification and validation of vertebral compression fractures using administrative claims data.

Jeffrey R Curtis1, Amy S Mudano, Daniel H Solomon, Juan Xi, Mary Elkins Melton, Kenneth G Saag.   

Abstract

INTRODUCTION: Vertebral compression fractures (VCFs) are the most common type of osteoporotic fracture. Administrative claims data might be useful to identify VCFs, but this approach to case finding has received limited evaluation.
METHODS: Using the administrative claims databases of a large regional US health care organization, we identified adults with a claim with a VCF diagnosis code from January 2003 to June 2004 and excluded persons with malignancy. We examined the positive predictive values (PPV) of several claims algorithms to correctly identify any confirmed (prevalent or incident) VCF, and separately, incident VCFs.
RESULTS: A total of 259 persons were identified with a VCF suspected based on their administrative claims data. A claims algorithm that required a VCF diagnosis on any claim had a PPV to identify any confirmed VCF of 87% (95% confidence interval (CI), 82-91%). The PPV of this algorithm to identify a confirmed incident VCF was 46% (95% CI, 37-54%). An algorithm that required a spine imaging test followed by a physician visit with a VCF code within 10 days, or a hospitalization with a primary diagnosis code, had higher PPVs (PPV = 93%; 95% CI, 87-98% for any confirmed VCF; PPV = 61%; 95% CI, 49-74% for incident VCFs).
CONCLUSIONS: A simple case finding approach to identify VCFs using administrative claims data can identify prevalent VCFs with high accuracy but misclassified more than half of incident VCFs. A more complex claims algorithm may be used but still will result in some misclassification of incident VCFs.

Entities:  

Mesh:

Year:  2009        PMID: 19106733      PMCID: PMC2711626          DOI: 10.1097/MLR.0b013e3181808c05

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  9 in total

1.  Comorbidity measures for use with administrative data.

Authors:  A Elixhauser; C Steiner; D R Harris; R M Coffey
Journal:  Med Care       Date:  1998-01       Impact factor: 2.983

2.  Internal validation of Medicare claims data.

Authors:  J A Baron; G Lu-Yao; J Barrett; D McLerran; E S Fisher
Journal:  Epidemiology       Date:  1994-09       Impact factor: 4.822

3.  Use of predictive value to adjust relative risk estimates biased by misclassification of outcome status.

Authors:  M S Green
Journal:  Am J Epidemiol       Date:  1983-01       Impact factor: 4.897

4.  Identification of fractures from computerized Medicare files.

Authors:  W A Ray; M R Griffin; R L Fought; M L Adams
Journal:  J Clin Epidemiol       Date:  1992-07       Impact factor: 6.437

5.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

Authors:  S T Harris; N B Watts; H K Genant; C D McKeever; T Hangartner; M Keller; C H Chesnut; J Brown; E F Eriksen; M S Hoseyni; D W Axelrod; P D Miller
Journal:  JAMA       Date:  1999-10-13       Impact factor: 56.272

6.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

Authors:  D M Black; S R Cummings; D B Karpf; J A Cauley; D E Thompson; M C Nevitt; D C Bauer; H K Genant; W L Haskell; R Marcus; S M Ott; J C Torner; S A Quandt; T F Reiss; K E Ensrud
Journal:  Lancet       Date:  1996-12-07       Impact factor: 79.321

7.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.

Authors:  S R Cummings; D M Black; D E Thompson; W B Applegate; E Barrett-Connor; T A Musliner; L Palermo; R Prineas; S M Rubin; J C Scott; T Vogt; R Wallace; A J Yates; A Z LaCroix
Journal:  JAMA       Date:  1998 Dec 23-30       Impact factor: 56.272

8.  Fracture risk with intermittent high-dose oral glucocorticoid therapy.

Authors:  Frank De Vries; Madelon Bracke; Hubert G M Leufkens; Jan-Willem J Lammers; Cyrus Cooper; Tjeerd P Van Staa
Journal:  Arthritis Rheum       Date:  2007-01

9.  Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study.

Authors:  S L Silverman; N B Watts; P D Delmas; J L Lange; R Lindsay
Journal:  Osteoporos Int       Date:  2006-11-15       Impact factor: 4.507

  9 in total
  46 in total

1.  Validation of diagnostic codes for subtrochanteric, diaphyseal, and atypical femoral fractures using administrative claims data.

Authors:  Pongthorn Narongroeknawin; Nivedita M Patkar; Bita Shakoory; Archana Jain; Jeffrey R Curtis; Elizabeth Delzell; Philip H Lander; Robert R Lopez-Ben; Michael J Pitt; Monika M Safford; David A Volgas; Kenneth G Saag
Journal:  J Clin Densitom       Date:  2011-11-09       Impact factor: 2.617

2.  Does medication adherence itself confer fracture protection? An investigation of the healthy adherer effect in observational data.

Authors:  Jeffrey R Curtis; Huifeng Yun; Jeff L Lange; Robert Matthews; Pradeep Sharma; Kenneth G Saag; Elizabeth Delzell
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-12       Impact factor: 4.794

3.  Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients.

Authors:  J M Neuner; T W Yen; R A Sparapani; P W Laud; A B Nattinger
Journal:  Osteoporos Int       Date:  2010-12-18       Impact factor: 4.507

4.  Institutionalization following incident non-traumatic fractures in community-dwelling men and women.

Authors:  S Morin; L M Lix; M Azimaee; C Metge; S R Majumdar; W D Leslie
Journal:  Osteoporos Int       Date:  2011-10-19       Impact factor: 4.507

5.  Duration of Bisphosphonate Drug Holidays and Associated Fracture Risk.

Authors:  Jeffrey R Curtis; Kenneth G Saag; Tarun Arora; Nicole C Wright; Huifeng Yun; Shanette Daigle; Robert Matthews; Elizabeth Delzell
Journal:  Med Care       Date:  2020-05       Impact factor: 2.983

6.  Correlation of hip fracture with other fracture types: Toward a rational composite hip fracture endpoint.

Authors:  Cathleen Colón-Emeric; Carl F Pieper; Janet Grubber; Lynn Van Scoyoc; Merritt L Schnell; Courtney Harold Van Houtven; Megan Pearson; Joanne Lafleur; Kenneth W Lyles; Robert A Adler
Journal:  Bone       Date:  2015-07-04       Impact factor: 4.398

7.  Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis.

Authors:  A Balasubramanian; S W Wade; R A Adler; C J F Lin; M Maricic; C D O'Malley; K Saag; J R Curtis
Journal:  Osteoporos Int       Date:  2016-06-08       Impact factor: 4.507

8.  Benzodiazepine Treatment and Fracture Risk in Young Persons With Anxiety Disorders.

Authors:  Greta A Bushnell; Tobias Gerhard; Stephen Crystal; Mark Olfson
Journal:  Pediatrics       Date:  2020-06-04       Impact factor: 7.124

9.  Comparative Fracture Risks Among United States Medicaid Enrollees With and Those Without Systemic Lupus Erythematosus.

Authors:  Sara K Tedeschi; Seoyoung C Kim; Hongshu Guan; Jennifer M Grossman; Karen H Costenbader
Journal:  Arthritis Rheumatol       Date:  2019-06-05       Impact factor: 10.995

10.  "Pathologic" fractures: should these be included in epidemiologic studies of osteoporotic fractures?

Authors:  J R Curtis; A J Taylor; R S Matthews; M N Ray; D J Becker; L C Gary; M L Kilgore; M A Morrisey; K G Saag; A Warriner; E Delzell
Journal:  Osteoporos Int       Date:  2009-01-29       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.